Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Handylab Inc. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are assigned to 2 distinct examiners. Each examiner is located in a different art unit, as there are 2 distinct art units reported for the portfolio. This indicates that the company's active matters are split between two different administrative groups without any overlap.
The busiest examiner for the company is KIM, YOUNG J, who is responsible for 1 pending office action. With 2 pending office actions and 2 distinct examiners, each examiner is handling a single case. Because these 2 examiners are in 2 distinct art units, practitioners will need to address the specific requirements of two different units while managing two separate examiner relationships. This decentralized structure requires managing two distinct perspectives on the company's technology. The focus on Biotechnology & Pharmaceuticals defines the current technical scope of the company's 2 pending office actions. Practitioners should expect independent examination processes for each active matter.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIM, YOUNG J | 1 | 64.8% | +18.1% |
| OLSON, ANDREA STEFFEL | 1 | 62.3% | -11.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18893295 | MICROFLUIDIC CARTRIDGE | KIM, YOUNG J | — |
| Art Unit | Apps |
|---|---|
| 1681 | 1 |
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18893295 | MICROFLUIDIC CARTRIDGE | KIM, YOUNG J | 1681 | §112DP | Non-Final OA | — | Pending | Sep 23, 2024 |
| 17674177 | POLYNUCLEOTIDE CAPTURE MATERIALS, AND SYSTEMS USING SAME | OLSON, ANDREA STEFFEL | 1693 | §103§112DP | Final Rejection | 91d overdue | Pending | Feb 17, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial